387 related articles for article (PubMed ID: 29455579)
1. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
Peckham AM; Nicewonder JA
J Pharm Pract; 2019 Aug; 32(4):450-457. PubMed ID: 29455579
[TBL] [Abstract][Full Text] [Related]
2. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
Citrome L
Expert Rev Neurother; 2018 Apr; 18(4):323-332. PubMed ID: 29557243
[TBL] [Abstract][Full Text] [Related]
3. Valbenazine in the treatment of tardive dyskinesia.
Witek N; Comella C
Neurodegener Dis Manag; 2019 Apr; 9(2):73-81. PubMed ID: 30724115
[TBL] [Abstract][Full Text] [Related]
4. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
Stahl SM
CNS Spectr; 2018 Aug; 23(4):239-247. PubMed ID: 30160230
[TBL] [Abstract][Full Text] [Related]
5. Deutetrabenazine in the treatment of tardive dyskinesia.
Niemann N; Jimenez-Shahed J
Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019
[TBL] [Abstract][Full Text] [Related]
6. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
Khorassani F; Luther K; Talreja O
Am J Health Syst Pharm; 2020 Jan; 77(3):167-174. PubMed ID: 31974564
[TBL] [Abstract][Full Text] [Related]
7. Valbenazine for the treatment of tardive dyskinesia.
Müller T
Expert Rev Neurother; 2017 Dec; 17(12):1135-1144. PubMed ID: 28971695
[TBL] [Abstract][Full Text] [Related]
8. Valbenazine for the treatment of tardive dyskinesia.
Barquero N
Drugs Today (Barc); 2016 Dec; 52(12):665-672. PubMed ID: 28276538
[TBL] [Abstract][Full Text] [Related]
9. Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia.
Med Lett Drugs Ther; 2018 Apr; 60(1545):65-68. PubMed ID: 29667946
[No Abstract] [Full Text] [Related]
10. Deuterium Tetrabenazine for Tardive Dyskinesia.
Cummings MA; Proctor GJ; Stahl SM
Clin Schizophr Relat Psychoses; 2018 Jan; 11(4):214-220. PubMed ID: 29341821
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
Niemann N; Jankovic J
Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
[TBL] [Abstract][Full Text] [Related]
12. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
Caroff SN; Aggarwal S; Yonan C
J Comp Eff Res; 2018 Feb; 7(2):135-148. PubMed ID: 28965423
[TBL] [Abstract][Full Text] [Related]
13. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.
Koch J; Shi WX; Dashtipour K
Pharmacol Ther; 2020 Aug; 212():107580. PubMed ID: 32454050
[TBL] [Abstract][Full Text] [Related]
14. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
Solmi M; Pigato G; Kane JM; Correll CU
Drug Des Devel Ther; 2018; 12():1215-1238. PubMed ID: 29795977
[TBL] [Abstract][Full Text] [Related]
15. How to Assess Tardive Dyskinesia Symptom Improvement With Measurement-Based Care.
McEvoy JP
J Clin Psychiatry; 2020 Nov; 81(6):. PubMed ID: 33147658
[TBL] [Abstract][Full Text] [Related]
16. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.
Claassen DO; Philbin M; Carroll B
Expert Opin Pharmacother; 2019 Dec; 20(18):2209-2221. PubMed ID: 31613641
[No Abstract] [Full Text] [Related]
17. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
Sarva H; Henchcliffe C
Expert Rev Clin Pharmacol; 2018 Mar; 11(3):209-217. PubMed ID: 29338466
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
[TBL] [Abstract][Full Text] [Related]
20. VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia.
Kim AP; Baker DE; Levien TL
Consult Pharm; 2018 Apr; 33(4):201-209. PubMed ID: 29609698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
